Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
600196 On Other Exchanges
Symbol
Exchange
600196 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fosun pharmaceuti-a (600196) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FOSUN PHARMACEUTI-A (600196)

Related News

No related news articles were found.

shanghai fosun pharmaceuti-a (600196) Related Businessweek News

No Related Businessweek News Found

shanghai fosun pharmaceuti-a (600196) Details

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, produces, trades, and sells pharmaceutical products in Mainland China and internationally. The company offers metabolism and alimentary tract drugs for the treatment of chronic hepatitis B, diabetes, chronic atrophic gastritis and gastralgia, flatulence, anorexia, eructation, and pyrosis; and anti-infection drugs to treat malaria, cefmetazole sodium sensitive bacterial infections, tuberculosis, sensitive gram-positive bacterial infections, and viral pneumonia and upper respiratory tract infections. It also provides cardiovascular and blood system drugs for antithrombotic treatment, ductus dependent congenital heart diseases, hypoxaemia relief, and chronic hepatitis; and the treatment of myocarditis, sinus syndrome, coronary heart disease, cardiomyopathy, arrhythmia, hypertension, microangiopathy, varicose veins syndrome, microcirculatory disorders, hypercholesterolemia, anemia, and chronic renal failure, as well for various dialysis treatments. In addition, the company offers oncology drugs for the treatment of lung, breast, prostate, gastric, colorectal, and nasopharyngeal cancers, as well as for malignant pleural mesothelioma; and vaccines for the prevention of influenza. Further, it provides central nervous system drugs; and crude drugs and intermediates. Additionally, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, imports, exports, and sells medical equipment and diagnostic products; provides healthcare and hospital management services, and consulting services; and manufactures and sells biologic pharmaceutical products. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

17,666 Employees
Last Reported Date: 08/25/15
Founded in 1994

shanghai fosun pharmaceuti-a (600196) Top Compensated Officers

Vice Chairman, Chief Executive Officer, Presi...
Total Annual Compensation: CNY4.6M
Executive Chairman, Chairman of Strategic Com...
Total Annual Compensation: CNY6.4M
Compensation as of Fiscal Year 2014.

shanghai fosun pharmaceuti-a (600196) Key Developments

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Aug 27, 2015

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Aug 27, 2015. Agenda: To discuss and approve issues including the proposal of meeting conditions for publicly issuing corporate bonds; to consider the proposal of scheme for issuing corporate bonds; and to consider the proposal of requesting the shareholders' meeting to fully authorize the directorate (or personages authorized by the directorate) to handle relevant issues of registration and issuance of corporate bonds.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Earnings Results for the First Half of 2015

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced earnings results for the first Half of 2015. For the period, basic earnings per share was CNY 0.56 and weighted average return on net assets was 7.48%.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2015 Results on Aug 26, 2015

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that they will report first half, 2015 results on Aug 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600196:CH CNY22.55 CNY +0.56

600196 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apollo Hospitals Enterprise Ltd 1,343 INR 0.00
Bangkok Dusit Medical Services PCL 19.40 THB +0.70
Bumrungrad Hospital PCL 222.00 THB -1.00
IHH Healthcare Bhd 5.85 MYR +0.06
KPJ Healthcare Bhd 4.20 MYR 0.00
View Industry Companies
 

Industry Analysis

600196

Industry Average

Valuation 600196 Industry Range
Price/Earnings 21.2x
Price/Sales 4.1x
Price/Book 2.9x
Price/Cash Flow 17.5x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FOSUN PHARMACEUTI-A, please visit www.fosunpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.